{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:04:40Z","timestamp":1739250280554,"version":"3.37.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.neuropharm.2009.04.018","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:20:03Z","timestamp":1245662403000},"page":"259-267","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological characterization of senktide-induced tail whips"],"prefix":"10.1016","volume":"58","author":[{"given":"Rebecca E.","family":"Nordquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa M.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Algeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Pauly-Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Spooren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2009.04.018_bib1","series-title":"Integrating the Neurobiology of Schizophrenia","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0074-7742(06)78005-9","article-title":"Alterations of serotonin transmission in schizophrenia: international review of neurobiology","author":"Abi-Dargham","year":"2007"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2174\/0929867043364748","article-title":"Tachykinins and tachykinin receptors: structure and activity relationships","volume":"11","author":"Almeida","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0306-4522(96)00328-4","article-title":"Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects","volume":"75","author":"Benes","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-3565(24)37123-X","article-title":"L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests","volume":"283","author":"Bristow","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib7","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.npp.1301549","article-title":"In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia","volume":"33","author":"Dawson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0024-3205(01)01214-0","article-title":"Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum","volume":"69","author":"Dean","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00221-005-0290-9","article-title":"Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia","volume":"168","author":"Deng","year":"2006","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0006-8993(91)91623-9","article-title":"Phylogeny of tachykinin receptor localization in the vertebrate central nervous system \u2013 apparent absence of Neurokinin-2 and Neurokinin-3 binding sites in the human brain","volume":"539","author":"Dietl","year":"1991","journal-title":"Brain. Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9861(19960108)364:2<290::AID-CNE8>3.0.CO;2-0","article-title":"Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat","volume":"364","author":"Ding","year":"1996","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib12","doi-asserted-by":"crossref","first-page":"PL27","DOI":"10.1016\/0024-3205(94)00413-M","article-title":"SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor","volume":"56","author":"Emonds-Alt","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0014-2999(86)90500-5","article-title":"Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics","volume":"121","author":"Gavish","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm980633c","article-title":"Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)","volume":"42","author":"Giardina","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drug."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(91)90387-6","article-title":"Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism","volume":"195","author":"Humpel","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib17","first-page":"225","article-title":"Proceedings: tail rattling in aggressive mice as a measure of tranquillizing activity of drugs","volume":"17","author":"Krsiak","year":"1975","journal-title":"Act. Nerv. Sup."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib18","first-page":"93","article-title":"Can social and agonistic interactions be used to detect anxiolytic activity of drugs?","volume":"167","author":"Krsiak","year":"1984","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-6147(00)01463-2","article-title":"The troubled story of tachykinins and neurokinins","volume":"21","author":"Maggi","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1124\/mol.107.042754","article-title":"Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains","volume":"73","author":"Malherbe","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0143-4179(98)90075-0","article-title":"Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig","volume":"32","author":"Marco","year":"1998","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib22","doi-asserted-by":"crossref","unstructured":"Medhurst, A.D., Parsons, A.A., Roberts, J.C., Hay, D.W.P., 1996. Characterization NK3 receptors. Rabbit isolated iris sphincter muscle. 120, 93\u2013101.","DOI":"10.1038\/sj.bjp.0700867"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ddstr.2006.11.013","article-title":"NK3 receptor antagonists for the treatment of schizophrenia","volume":"3","author":"Meltzer","year":"2006","journal-title":"Drug Discov. Today: Ther. Strateg."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0306-4522(98)00349-2","article-title":"Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study","volume":"89","author":"Mileusnic","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.ne.14.030191.001011","article-title":"Mammalian tachykinin receptors","volume":"14","author":"Nakanishi","year":"1991","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0306-4522(96)00625-2","article-title":"Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study","volume":"78","author":"Nalivaiko","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pnpbp.2006.07.004","article-title":"Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia","volume":"31","author":"Newell","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000139393","article-title":"Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor","volume":"52","author":"Nguyen-Le","year":"1996","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00213-008-1119-6","article-title":"Cognitive performance in neurokinin 3 receptor knockout mice","volume":"198","author":"Nordquist","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2008.10.011","article-title":"The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils","volume":"600","author":"Nordquist","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FBP.0b013e32830cd7f5","article-title":"Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels and dopamine receptor levels in Neurokinin 3 receptor knockout mice","volume":"19","author":"Nordquist","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0014-2999(92)90251-X","article-title":"Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat","volume":"213","author":"Overton","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-1781(97)00060-7","article-title":"Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects","volume":"71","author":"Pandey","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0022-3565(25)10452-7","article-title":"Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist","volume":"263","author":"Pugsley","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1054\/npep.1999.0021","article-title":"Tachykinin NK(3)receptor involvement in anxiety","volume":"33","author":"Ribeiro","year":"1999","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2009.04.018_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cne.20664","article-title":"Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain","volume":"490","author":"Rigby","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.pbb.2006.03.013","article-title":"Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils","volume":"83","author":"Salom\u00e9","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3565(24)38912-8","article-title":"Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist","volume":"295","author":"Sarau","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0022-3565(24)36725-4","article-title":"Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective Neurokinin-3 receptor antagonist","volume":"281","author":"Sarau","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(99)00259-9","article-title":"The tachykinin NK1 receptor in the brain: pharmacology and putative functions","volume":"375","author":"Saria","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(94)00681-V","article-title":"Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices","volume":"273","author":"Seabrook","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2006.11.009","article-title":"The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined","volume":"90","author":"Skilbeck","year":"2007","journal-title":"Schizophr Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd1905","article-title":"NK3 receptor antagonists: the next generation of antipsychotics?","volume":"4","author":"Spooren","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1023\/A:1020796200769","article-title":"Clozapine and several other antipsychotic\/antidepressant drugs preferentially block the same \u2018core\u2019 fraction of GABA(A) receptors","volume":"23","author":"Squires","year":"1998","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1476-5381.1988.tb11527.x","article-title":"The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats","volume":"94","author":"Stoessl","year":"1988","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib49","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/mol.106.029868","article-title":"Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition","volume":"71","author":"Tian","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/(SICI)1096-9861(19970609)382:3<394::AID-CNE6>3.0.CO;2-Z","article-title":"Neurokinin receptor mRNA localization in human midbrain dopamine neurons","volume":"382","author":"Whitty","year":"1997","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2009.04.018_bib51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1254\/jjp.32.1111","article-title":"Pharmaco-ethological analysis of agonistic behavior between resident and intruder mice: effect of anticholinergic drugs","volume":"32","author":"Yoshimura","year":"1982","journal-title":"Jpn.\u00a0J.\u00a0Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:39:29Z","timestamp":1739173169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390809001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0028390809001683"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.04.018","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}